PL4229056T3 - Związki triazolopirydynylu jako inhibitory kinaz - Google Patents

Związki triazolopirydynylu jako inhibitory kinaz

Info

Publication number
PL4229056T3
PL4229056T3 PL21805787.5T PL21805787T PL4229056T3 PL 4229056 T3 PL4229056 T3 PL 4229056T3 PL 21805787 T PL21805787 T PL 21805787T PL 4229056 T3 PL4229056 T3 PL 4229056T3
Authority
PL
Poland
Prior art keywords
triazolopyridinyl
compounds
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
PL21805787.5T
Other languages
English (en)
Inventor
Guanglin Luo
Jie Chen
Carolyn Diane Dzierba
David B. Frennesson
Junqing Guo
Amy C. HART
Xirui HU
Michael E. Mertzman
Matthew Reiser Patton
Jianliang Shi
Steven H. Spergel
Brian Lee Venables
Yong-Jin Wu
Zili Xiao
Michael G. Yang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL4229056T3 publication Critical patent/PL4229056T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL21805787.5T 2020-10-19 2021-10-18 Związki triazolopirydynylu jako inhibitory kinaz PL4229056T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063093463P 2020-10-19 2020-10-19
PCT/US2021/055340 WO2022086828A1 (en) 2020-10-19 2021-10-18 Triazolopyridinyl compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL4229056T3 true PL4229056T3 (pl) 2024-06-10

Family

ID=78536657

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21805787.5T PL4229056T3 (pl) 2020-10-19 2021-10-18 Związki triazolopirydynylu jako inhibitory kinaz

Country Status (26)

Country Link
US (3) US11767322B2 (pl)
EP (2) EP4364737A3 (pl)
JP (1) JP7730897B2 (pl)
KR (1) KR20230092960A (pl)
CN (1) CN116802181A (pl)
AR (1) AR123793A1 (pl)
AU (1) AU2021364302A1 (pl)
CA (1) CA3196059A1 (pl)
CL (1) CL2023001123A1 (pl)
CO (1) CO2023004926A2 (pl)
DK (1) DK4229056T3 (pl)
ES (1) ES2987662T3 (pl)
FI (1) FI4229056T3 (pl)
HR (1) HRP20240739T1 (pl)
HU (1) HUE067776T2 (pl)
IL (1) IL302113A (pl)
LT (1) LT4229056T (pl)
MX (1) MX2023004492A (pl)
PE (1) PE20240219A1 (pl)
PL (1) PL4229056T3 (pl)
PT (1) PT4229056T (pl)
RS (1) RS65620B1 (pl)
SI (1) SI4229056T1 (pl)
SM (1) SMT202400242T1 (pl)
TW (1) TW202233614A (pl)
WO (1) WO2022086828A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2021067654A1 (en) 2019-10-03 2021-04-08 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN121969620A (zh) 2023-09-27 2026-05-01 百时美施贵宝公司 作为激酶抑制剂的三唑并吡啶醚连接的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1717238A4 (en) 2004-02-16 2008-03-05 Daiichi Seiyaku Co FUNGICIDES HETEROCYCLIC COMPOUNDS
AU2005260031B2 (en) 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
CA2750517A1 (en) 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
HK1219737A1 (zh) 2013-06-10 2017-04-13 Bayer Pharma Aktiengesellschaft 用於治疗癌症的新化合物
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
US10709133B2 (en) 2015-11-05 2020-07-14 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
DK3704118T3 (da) * 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
US20220177462A1 (en) 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
WO2021067654A1 (en) 2019-10-03 2021-04-08 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
CN114230565B (zh) 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
EP4229056A1 (en) 2023-08-23
TW202233614A (zh) 2022-09-01
WO2022086828A1 (en) 2022-04-28
AU2021364302A9 (en) 2024-05-02
JP7730897B2 (ja) 2025-08-28
SI4229056T1 (sl) 2024-06-28
AU2021364302A1 (en) 2023-06-22
EP4229056B1 (en) 2024-04-10
US20240425505A1 (en) 2024-12-26
HRP20240739T1 (hr) 2024-08-30
EP4364737A3 (en) 2024-08-07
US12110290B2 (en) 2024-10-08
ES2987662T3 (es) 2024-11-15
PE20240219A1 (es) 2024-02-16
KR20230092960A (ko) 2023-06-26
CO2023004926A2 (es) 2023-05-08
US20240109888A1 (en) 2024-04-04
JP2023546166A (ja) 2023-11-01
HUE067776T2 (hu) 2024-11-28
IL302113A (en) 2023-06-01
EP4364737A2 (en) 2024-05-08
US20220119388A1 (en) 2022-04-21
CL2023001123A1 (es) 2023-09-22
PT4229056T (pt) 2024-05-21
CN116802181A (zh) 2023-09-22
LT4229056T (lt) 2024-06-10
FI4229056T3 (fi) 2024-06-18
US11767322B2 (en) 2023-09-26
AR123793A1 (es) 2023-01-11
DK4229056T3 (da) 2024-07-15
CA3196059A1 (en) 2022-04-28
MX2023004492A (es) 2023-05-10
SMT202400242T1 (it) 2024-07-09
RS65620B1 (sr) 2024-07-31

Similar Documents

Publication Publication Date Title
IL290527A (en) Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL292642A (en) Ras inhibitors
IL290779A (en) Heterocyclic rip1 kinase inhibitors
PL3999506T3 (pl) Inhibitory parp1
EP4003993A4 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
EP3752491A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
EP4007756C0 (en) KIF18A INHIBITORS
PL4229056T3 (pl) Związki triazolopirydynylu jako inhibitory kinaz
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
IL289439A (en) Heterocyclic compounds as bet inhibitors
PL3870574T3 (pl) Pochodne aminopirymidyny/pirazyny jako inhibitory CTPS1
PL4051688T3 (pl) Inhibitory cd73
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
PL3442535T3 (pl) Związki heterocykliczne jako inhibitory kinazy ret
HUE058998T2 (hu) Heteroaril vegyületek, mint kináz inhibitorok
EP3804707A4 (en) KINASE INHIBITOR
HUE057970T2 (hu) Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
PL4182308T3 (pl) Pochodne pirydazynyloaminowe jako inhibitory ALK5
EP3962908A4 (en) HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
PL4010330T3 (pl) Pochodne chinoliny jako inhibitory kinazy białkowej
EP3849985A4 (en) ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS